Hemoglobin targeted therapeutics - early stage development of a novel class of plasma protein products to control hemolysis mediated adverse effects

• Unité de recherche: INNOSUISSE
• Numéro de projet: 13265.1 PFLS-LS
• Titre du projet anglais: Hemoglobin targeted therapeutics - early stage development of a novel class of plasma protein products to control hemolysis mediated adverse effects

Description succincte (Allemand)

Hemoglobin targeted therapeutics - early stage development of a novel class of plasma protein products to control hemolysis mediated adverse effects

Description succincte (Anglais)

Hemoglobin targeted therapeutics - early stage development of a novel class of plasma protein products to control hemolysis mediated adverse effects

Résumé des résultats (Abstract) (Allemand)

Red blood cell destruction results in direct contact of released free hemoglobin with susceptible tissues.|Ensuing adverse effects include renal damage, hemodynamic instability and inflammation in patients|receiving massive blood transfusion or extracorporeal cardio-pulmonary support or with hemolytic anemia.|In this project novel plasma derived bio-therapeutics will be developed that will for the first time allow for|targeted prevention of hemoglobin-driven adverse outcomes with the goal of increasing safety of blood|transfusion and critical care.

Résumé des résultats (Abstract) (Anglais)

Red blood cell destruction results in direct contact of released free hemoglobin with susceptible tissues.|Ensuing adverse effects include renal damage, hemodynamic instability and inflammation in patients|receiving massive blood transfusion or extracorporeal cardio-pulmonary support or with hemolytic anemia.|In this project novel plasma derived bio-therapeutics will be developed that will for the first time allow for|targeted prevention of hemoglobin-driven adverse outcomes with the goal of increasing safety of blood|transfusion and critical care.